β-Blockers in sepsis: Reexamining the evidence

Nathan M. Novotny, Tim Lahm, Troy A. Markel, Paul R. Crisostomo, Meijing Wang, Yue Wang, Rinki Ray, Jiangning Tan, Dalia Al-Azzawi, Daniel R. Meldrum

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Sepsis remains the leading cause for noncardiac intensive care unit deaths in the United States. Despite recent advances in the treatment of this devastating condition, mortality and morbidity remain unacceptably high. Sepsis is characterized by a multitude of pathophysiological changes that include inflammation, metabolic derangements, hemodynamic alterations, and multiorgan dysfunction. Unfortunately, several studies of treatment modalities aimed at correcting one or more of the underlying derangements have led to disappointing results. New treatment modalities are needed. β-Receptor blockers have long been used for a variety of conditions such as coronary artery disease, congestive heart failure, and arterial hypertension. Recent data suggest that β-blocker effects on metabolism, glucose homeostasis, cytokine expression, and myocardial function may be beneficial in the setting of sepsis. Although treating a potentially hypotensive condition with a drug with antihypertensive properties may initially seem counterintuitive, the metabolic and immunomodulatory properties of β-blockers may be of benefit. It is the purpose of this review to discuss the effects of β- blockers on the following: (1) metabolism, (2) glucose regulation, (3) the inflammatory response, (4) cardiac function, and (5) mortality in sepsis.

Original languageEnglish
Pages (from-to)113-119
Number of pages7
JournalShock
Volume31
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Sepsis
Glucose
Mortality
Antihypertensive Agents
Intensive Care Units
Coronary Artery Disease
Homeostasis
Heart Failure
Hemodynamics
Cytokines
Hypertension
Inflammation
Morbidity

Keywords

  • β-adrenergic receptor
  • Cytokines
  • Endotoxin
  • Esmolol
  • LPS
  • Propranolol
  • Shock

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Cite this

Novotny, N. M., Lahm, T., Markel, T. A., Crisostomo, P. R., Wang, M., Wang, Y., ... Meldrum, D. R. (2009). β-Blockers in sepsis: Reexamining the evidence. Shock, 31(2), 113-119. https://doi.org/10.1097/SHK.0b013e318180ffb6

β-Blockers in sepsis : Reexamining the evidence. / Novotny, Nathan M.; Lahm, Tim; Markel, Troy A.; Crisostomo, Paul R.; Wang, Meijing; Wang, Yue; Ray, Rinki; Tan, Jiangning; Al-Azzawi, Dalia; Meldrum, Daniel R.

In: Shock, Vol. 31, No. 2, 02.2009, p. 113-119.

Research output: Contribution to journalArticle

Novotny, NM, Lahm, T, Markel, TA, Crisostomo, PR, Wang, M, Wang, Y, Ray, R, Tan, J, Al-Azzawi, D & Meldrum, DR 2009, 'β-Blockers in sepsis: Reexamining the evidence', Shock, vol. 31, no. 2, pp. 113-119. https://doi.org/10.1097/SHK.0b013e318180ffb6
Novotny, Nathan M. ; Lahm, Tim ; Markel, Troy A. ; Crisostomo, Paul R. ; Wang, Meijing ; Wang, Yue ; Ray, Rinki ; Tan, Jiangning ; Al-Azzawi, Dalia ; Meldrum, Daniel R. / β-Blockers in sepsis : Reexamining the evidence. In: Shock. 2009 ; Vol. 31, No. 2. pp. 113-119.
@article{7f7225cb919046449af7e9bf21100902,
title = "β-Blockers in sepsis: Reexamining the evidence",
abstract = "Sepsis remains the leading cause for noncardiac intensive care unit deaths in the United States. Despite recent advances in the treatment of this devastating condition, mortality and morbidity remain unacceptably high. Sepsis is characterized by a multitude of pathophysiological changes that include inflammation, metabolic derangements, hemodynamic alterations, and multiorgan dysfunction. Unfortunately, several studies of treatment modalities aimed at correcting one or more of the underlying derangements have led to disappointing results. New treatment modalities are needed. β-Receptor blockers have long been used for a variety of conditions such as coronary artery disease, congestive heart failure, and arterial hypertension. Recent data suggest that β-blocker effects on metabolism, glucose homeostasis, cytokine expression, and myocardial function may be beneficial in the setting of sepsis. Although treating a potentially hypotensive condition with a drug with antihypertensive properties may initially seem counterintuitive, the metabolic and immunomodulatory properties of β-blockers may be of benefit. It is the purpose of this review to discuss the effects of β- blockers on the following: (1) metabolism, (2) glucose regulation, (3) the inflammatory response, (4) cardiac function, and (5) mortality in sepsis.",
keywords = "β-adrenergic receptor, Cytokines, Endotoxin, Esmolol, LPS, Propranolol, Shock",
author = "Novotny, {Nathan M.} and Tim Lahm and Markel, {Troy A.} and Crisostomo, {Paul R.} and Meijing Wang and Yue Wang and Rinki Ray and Jiangning Tan and Dalia Al-Azzawi and Meldrum, {Daniel R.}",
year = "2009",
month = "2",
doi = "10.1097/SHK.0b013e318180ffb6",
language = "English",
volume = "31",
pages = "113--119",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - β-Blockers in sepsis

T2 - Reexamining the evidence

AU - Novotny, Nathan M.

AU - Lahm, Tim

AU - Markel, Troy A.

AU - Crisostomo, Paul R.

AU - Wang, Meijing

AU - Wang, Yue

AU - Ray, Rinki

AU - Tan, Jiangning

AU - Al-Azzawi, Dalia

AU - Meldrum, Daniel R.

PY - 2009/2

Y1 - 2009/2

N2 - Sepsis remains the leading cause for noncardiac intensive care unit deaths in the United States. Despite recent advances in the treatment of this devastating condition, mortality and morbidity remain unacceptably high. Sepsis is characterized by a multitude of pathophysiological changes that include inflammation, metabolic derangements, hemodynamic alterations, and multiorgan dysfunction. Unfortunately, several studies of treatment modalities aimed at correcting one or more of the underlying derangements have led to disappointing results. New treatment modalities are needed. β-Receptor blockers have long been used for a variety of conditions such as coronary artery disease, congestive heart failure, and arterial hypertension. Recent data suggest that β-blocker effects on metabolism, glucose homeostasis, cytokine expression, and myocardial function may be beneficial in the setting of sepsis. Although treating a potentially hypotensive condition with a drug with antihypertensive properties may initially seem counterintuitive, the metabolic and immunomodulatory properties of β-blockers may be of benefit. It is the purpose of this review to discuss the effects of β- blockers on the following: (1) metabolism, (2) glucose regulation, (3) the inflammatory response, (4) cardiac function, and (5) mortality in sepsis.

AB - Sepsis remains the leading cause for noncardiac intensive care unit deaths in the United States. Despite recent advances in the treatment of this devastating condition, mortality and morbidity remain unacceptably high. Sepsis is characterized by a multitude of pathophysiological changes that include inflammation, metabolic derangements, hemodynamic alterations, and multiorgan dysfunction. Unfortunately, several studies of treatment modalities aimed at correcting one or more of the underlying derangements have led to disappointing results. New treatment modalities are needed. β-Receptor blockers have long been used for a variety of conditions such as coronary artery disease, congestive heart failure, and arterial hypertension. Recent data suggest that β-blocker effects on metabolism, glucose homeostasis, cytokine expression, and myocardial function may be beneficial in the setting of sepsis. Although treating a potentially hypotensive condition with a drug with antihypertensive properties may initially seem counterintuitive, the metabolic and immunomodulatory properties of β-blockers may be of benefit. It is the purpose of this review to discuss the effects of β- blockers on the following: (1) metabolism, (2) glucose regulation, (3) the inflammatory response, (4) cardiac function, and (5) mortality in sepsis.

KW - β-adrenergic receptor

KW - Cytokines

KW - Endotoxin

KW - Esmolol

KW - LPS

KW - Propranolol

KW - Shock

UR - http://www.scopus.com/inward/record.url?scp=59649088065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649088065&partnerID=8YFLogxK

U2 - 10.1097/SHK.0b013e318180ffb6

DO - 10.1097/SHK.0b013e318180ffb6

M3 - Article

C2 - 18636043

AN - SCOPUS:59649088065

VL - 31

SP - 113

EP - 119

JO - Shock

JF - Shock

SN - 1073-2322

IS - 2

ER -